You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
海南海藥(000566.SZ):子公司擬1億港元認購中國抗體發行的1年期可轉債
格隆匯 12-22 21:20

格隆匯 12 月 22日丨海南海藥(000566.SZ)公佈,公司全資子公司海藥國際集團有限公司(“海藥國際”)於2020年12月22日與中國抗體制藥有限公司(“中國抗體”)簽署《中國抗體制藥有限公司及海藥國際集團有限公司港幣1億元2022年到期的可換股債券認購協議》(“認購協議”)。海南海藥擬以自籌資金1億港元認購中國抗體發行的1年期可轉債。

海南海藥聚焦醫藥主業,關注單克隆抗體、幹細胞等生物製藥前沿生命科學領域,開展創新藥物與治療技術的前沿研發。中國抗體在單克隆抗體領域具有豐富的研發經驗,產品管線在國內處於先進水平,技術優勢突出、產業化基礎良好。同時,海南海藥持有中國抗體約1.59億股股份,佔已發行普通股比例為15.79%,為中國抗體第三大股東,中國抗體經營情況對海南海藥具有重要影響。海南海藥擬通過子公司海藥國際認購中國抗體可轉換債券。並根據中國抗體在研產品的具體推進情況和中國抗體發展情況,適時考慮下一步是否行權將債券轉換為中國抗體股票。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account